Our top pick for
Molecular Data Inc is a chemicals business based in the US. Molecular Data shares (MKD) are listed on the NASDAQ and all prices are listed in US Dollars. Molecular Data employs 189 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$0.42|
|52-week range||$0.27 - $2.23|
|50-day moving average||$0.36|
|200-day moving average||$0.67|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.27|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-21)||16.93%|
|1 month (2021-09-28)||42.46%|
|3 months (2021-07-28)||-30.37%|
|6 months (2021-04-28)||-56.08%|
|1 year (2020-10-27)||-61.57%|
|2 years (2019-10-24)||N/A|
|3 years (2018-10-24)||N/A|
|5 years (2016-10-24)||N/A|
|Revenue TTM||$4.6 billion|
|Gross profit TTM||$-10,199,000|
|Return on assets TTM||-21.43%|
|Return on equity TTM||-4936.16%|
|Market capitalisation||$57.5 million|
TTM: trailing 12 months
There are currently 1.9 million Molecular Data shares held short by investors – that's known as Molecular Data's "short interest". This figure is 12% down from 2.2 million last month.
There are a few different ways that this level of interest in shorting Molecular Data shares can be evaluated.
Molecular Data's "short interest ratio" (SIR) is the quantity of Molecular Data shares currently shorted divided by the average quantity of Molecular Data shares traded daily (recently around 12.6 million). Molecular Data's SIR currently stands at 0.15. In other words for every 100,000 Molecular Data shares traded daily on the market, roughly 150 shares are currently held short.
However Molecular Data's short interest can also be evaluated against the total number of Molecular Data shares, or, against the total number of tradable Molecular Data shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Molecular Data's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Molecular Data shares in existence, roughly 10 shares are currently held short) or 0.0209% of the tradable shares (for every 100,000 tradable Molecular Data shares, roughly 21 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Molecular Data.
Find out more about how you can short Molecular Data stock.
We're not expecting Molecular Data to pay a dividend over the next 12 months.
Molecular Data Inc. , through its subsidiaries, operates in the chemical e-commerce business in the People's Republic of China. The company operates technology-driven platform that connects participants along the chemical value chain through its integrated solutions. It delivers e-commerce solutions, financial solutions, warehousing and logistics solutions, and software-as-a-service suites for participants in the traditional chemical industry. The company offers its e-commerce solutions through online platform that consists of molbase. com and molbase. cn websites; Moku Data Weixin account; Chemical Community app; and other ancillary platforms.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.